A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs TG 4010 (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 20 Nov 2017 Status changed from planning to not yet recruiting.
    • 11 Sep 2017 According to a Transgene media release, US FDA granted Investigational New Drug (IND) clearance to proceed with this trial and first patient is expected to be included into this Phase 2 study at the end of 2017.
    • 26 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top